Vectura at a glance
Vectura Group plc is a pulmonary drug development company focused principally on the development of a range of inhaled pharmaceuticals for the treatment of respiratory and neurological diseases.
Vectura has a broad pipeline of products in development that use its proprietary device and formulation technologies and, also has a portfolio of revenue-generating, marketed products.
Product pipeline: Vectura has a broad development pipeline that combines mid and late stage programmes with earlier stage opportunities:
Respiratory
Budesonide
Clickhaler®/asthma
NVA237/COPD
QVA149/COPD
VR315/asthma
Duohaler® Projects 1 and 2 asthma/COPD
Boehringer Ingelheim respiratory products
VR496/cystic fibrosis/COPD
VR694/asthma
Neurology
VR040/Parkinson's disease
VR147/migraine
Other indications
VR004/erectile dysfunction
VR776/premature ejaculation
Inhaled insulin/diabetes
Marketed products: Vectura receives royalty income from a portfolio of eight revenue-generating, marketed products, both respiratory and non-respiratory products, which helps to funds Vectura’s product development, listed as follows:
Asmasal®
Asmabec®
Budesonide Clickhaler®
Formoterol Clickhaler®
Meptin® Clickhaler®
Adept®
Extraneal®
ADVATE®
Proprietary technologies: Vectura has the complete
range of device and formulation technologies (listed below) to take
an API and deliver a finished inhaled pharmaceutical product.
Vectura has proven its ability to industrialise its products for
marketing purposes.
Aspirair®
GyroHaler®
Clickhaler®
Duohaler®
S2™ Unit Dose
PowderHale®
Other formulation techniques
Vectura’s product development strategy is to combine its
proprietary device and formulation technologies with existing
off-patent or clinically validated drugs, some of which are
repurposed to treat new indications, with inhalation as an
improved, more effective route of delivery, or to treat the same
indication, with inhalation as an improved, more effective route of
delivery.
Partnerships: Vectura develops pulmonary products in-house and in collaboration with its pharmaceutical partners and out-licenses certain products that require significant resources for later stage development and commercialisation. The Company also selectively out-licenses its device and formulation technologies to other companies. Its partners include Baxter, Boehringer Ingelheim, Merck KgaA, Novartis, UCB and Otsuka.
Intellectual property: Vectura protects its products and technologies, which include patents, trademarks, design rights and confidential know-how. The patent portfolio comprises about 135 families with patents in the key territories of the United States, Japan and the main European member states. Vectura vigorously maintains and protects its intellectual property estate.
Vectura’s Executive Management
team:
Dr Chris Blackwell, Chief Executive
Anne Hyland, Chief Financial Officer and Company Secretary
Dr Tim Wright, Commercial Director
Dr Mark Main, Development Director
Dr Martin Shott, Pharmaceutical Operations Director
Stephen Eason, Director of Device Development
Dr Colin Dalton, Director of IP and Corporate Affairs
The Board of Directors:
John “Jack” Cashman, Non-Executive Chairman
Dr Andrew Richards, Non-Executive Director
Dr Susan Foden, Non-Executive Director
Dr John Brown, Non-Executive Director
Dr Chris Blackwell, Chief Executive
Anne Hyland, Chief Financial Officer and Company Secretary
Locations: Vectura is based in the UK with headquarters and development operations in Chippenham, Wiltshire with further laboratories in Nottingham and device development in Cambridge.
AIM listed: Vectura’s shares are traded on the London Stock Exchange under the symbol VEC.
